PTCT - CIK 0001070081
The table below shows PTC THERAPEUTICS, INC.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | $711.20M | -$107.69M | -$158.42M | -$356.65M | -$251.33M | -$194.07M |
| Capital expenditure | $8.86M | $6.50M | $28.44M | $32.02M | $28.21M | $17.84M |
| Investing cash flow | -$861.98M | $44.18M | -$176.74M | $290.18M | $219.18M | -$561.55M |
| Dividends paid | - | - | - | - | - |
PTC THERAPEUTICS, INC. reported operating cash flow of $711.20M for fiscal year 2025. That is up 760.4% from -$107.69M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from -$103.57M (FY 2016) to $711.20M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $331.09M | $255.87M | $646.40M | $167.95M | $20.88M | $668.72M |